Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov. 2013;12:595–610.

Article  CAS  PubMed  Google Scholar 

El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–73.

Article  PubMed  Google Scholar 

Hoshida Y, Fuchs BC, Bardeesy N, et al. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79-90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645–53.

Article  CAS  PubMed  Google Scholar 

Zeuzem S, Serfaty L, Vierling J, et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018;53:679–88.

Article  CAS  PubMed  Google Scholar 

Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018;53:557–65.

Article  PubMed  Google Scholar 

Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and Safety of Sofosbuvir-Velpatasvir With or Without Ribavirin in HCV-infected Japanese Patients With Decompensated Cirrhosis: An Open-Label Phase 3 Trial. J Gastroenterol. 2019;54:87–95.

Article  CAS  PubMed  Google Scholar 

D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995;22:332–54.

Article  CAS  PubMed  Google Scholar 

Lay CS, Tsai YT, Teg CY, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology. 1997;25:1346–50.

Article  CAS  PubMed  Google Scholar 

Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Dig Dis. 2016;34:382–6.

Article  PubMed  Google Scholar 

Pagliaro L, D’Amico G, Sörensen TI, et al. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med. 1992;117:59–70.

Article  CAS  PubMed  Google Scholar 

Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–10.

Article  PubMed  Google Scholar 

Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–24.

Article  CAS  PubMed  Google Scholar 

Rockey DC, Friedman SL. Fibrosis regression after eradication of hepatitis C virus: from bench to bedside. Gastroenterology. 2021;160:1502–20.

Article  CAS  PubMed  Google Scholar 

Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996–1005.

Article  CAS  PubMed  Google Scholar 

McDonald SA, Pollock KG, Barclay ST, et al. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. J Viral Hepat. 2020;27:270–80.

Article  CAS  PubMed  Google Scholar 

El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154:2111–21.

Article  CAS  PubMed  Google Scholar 

Tachi Y, Hirai T, Miyata A, et al. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res. 2015;45:238–46.

Article  CAS  PubMed  Google Scholar 

Fernández CC, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology. 2017;65:1810–22.

Article  PubMed  Google Scholar 

Nagaoki Y, Aikata H, Kobayashi T, et al. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. J Gastroenterol. 2013;48:847–55.

Article  CAS  PubMed  Google Scholar 

Puigvehí M, Londoño MC, Torras X, et al. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. J Gastroenterol. 2020;55:205–16.

Article  PubMed  Google Scholar 

Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–6.

Article  CAS  PubMed  Google Scholar 

Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805.

Article  PubMed  Google Scholar 

Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices. Digest Endoscopy. 2010;22:1–9.

Article  Google Scholar 

Di Marco V, Calvaruso V, Ferraro D, et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology. 2016;151:130–9.

Article  PubMed  Google Scholar 

Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–9.

Article  PubMed  Google Scholar 

Tsuji S, Uchida Y, Uemura H, et al. Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol Res. 2020;50:512–23.

Article  CAS  PubMed  Google Scholar 

Nagaoki Y, Imamura M, Teraoka Y, et al. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res. 2020;50:1222–33.

Article  CAS  PubMed  Google Scholar 

Lens S, Alvarado-Tapias E, Mariño Z, et al. Effects of All-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153:1273–83.

Article  CAS  PubMed  Google Scholar 

Ramanathan S, Khandelwal N, Kalra N, et al. Correlation of HVPG level with ctp score, MELD Score, ascites, size of varices, and etiology in cirrhotic patients. Saudi J Gastroenterol. 2016;22:109–15.

Article  PubMed  PubMed Central  Google Scholar 

Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020;73:1415–24.

Article  PubMed  Google Scholar 

Mandorfer M, Kozbial K, Freissmuth C, et al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther. 2015;42:707–18.

Article  CAS  PubMed  Google Scholar 

Qamar AA, Grace ND, Groszmann RJ, et al. Platelet count is not a predictor of the p